Early detection is vital for prolonging 5-year survival for patients with gastric cancer (GC). Numerous studies indicate that circulating long non-coding RNAs (lncRNAs) can be used to diagnose malignant tumours. This study aimed to investigate the capacity of novel lncRNAs for diagnosing GC. A lncRNA microarray assay was used to screen differentially expressed lncRNAs between plasma of patients with GC and healthy controls. Plasma samples from 100 patients with healthy controls were used to construct a multiple-gene panel. An additional 50 pairs of GC patients with healthy controls were used to evaluate the diagnostic accuracy of the panel. Expression levels of lncRNAs were quantified through real-time polymerase chain reaction.
in multiple biological processes. 7 NcRNAs have been detected in many body fluids such as plasma, gastric juice, urine, and saliva. 8 Researchers have also demonstrated that extracellular ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), can be used as diagnostic tools for conditions including heart failure, 9 infectious diseases, 10 type 2 diabetes 11 and malignant tumours such as GC, 12, 13 lung cancer 14 and hepatocellular cancer. 15 Examples include lncRNA SPRY4-IT1 for diagnosis of hepatocellular carcinoma; 16 miR-22-3p, miR-642b-3p and miR-885-5p for diagnosis of pancreatic cancer; 17 and lncRNA MACC1 for diagnosis of non-smallcell lung cancer. 18 Although many publications have demonstrated high accuracies and efficiencies for ncRNAs-based diagnostic markers, the method is still controversial and far from clinical use due to the lack of largescale validation and consensus among researchers. 19 In this study, with the aim to find novel biomarkers for GC, we detected dysregulated lncRNAs in patients with GC vs healthy controls based on the results of lncRNA microarray and investigated the diagnostic potential of plasma-circulating lncRNAs.
| MATERIALS AND METHODS

| Study design, patients and plasma sample collections
A multiphase, case-control study was conducted, and the whole study was divided into four phases: the discovery phase, testing phase, training phase and validation phase. In the discovery phase, lncRNA profiling analyses were conducted between plasma from four GC patients with age-and gender-matched healthy controls.
The top 15 differentially expressed lncRNAs were identified for further analysis in the next phase. In the testing phase, candidate lncRNAs were analysed in another 20 GC patients with matched healthy controls and in cell lines via real-time polymerase chain reaction (PCR). Consistently, dysregulated lncRNAs were further investigated in the training phase, with 100 patients and 100 healthy controls. A combination of several lncRNAs was selected as a panel of GC diagnostic markers using a logistic regression model according to the real-time PCR results. In the validation phase, the diagnostic values of the plasma lncRNAs were estimated in another 100 individuals (including GC patients with 50
and 50 healthy controls), and correlations between the lncRNA expression levels and the clinicopathological parameters of the patients were examined.
All enrolled patients with GC were diagnosed at The First Hospital of China Medical University (Shenyang, China) by histopathological examination after radical resection or endoscopic biopsy.
Clinicopathological data were obtained from the medical records. was calculated using the Ct method normalized to b-actin. All the human gene-specific primers for real-time PCR are shown in Table S1 . Samples with a Ct > 40 were considered negative, as previously described. Table S2 ).
| Statistical analysis
| Discovery phase: Screening of candidate lncRNAs by microarray
The Human lncRNA V6 Microarray (Agilent) was used to screen for differential expression of lncRNAs in plasma samples from 4 patients with GC and 4 healthy controls. Fold change (GC vs Healthy) and P value were calculated from the normalized expression. Clustering analysis and heatmaps were used to show differentially expressed lncRNAs between the plasma samples from patients with GC and healthy controls (P < .05). We found that 267 lncRNAs were differentially expressed between these two groups. Among them, 256 lncRNAs were up-regulated in the plasma of GC patients compared with healthy controls, and 11 lncRNAs were down-regulated (Figure 1) . The detailed lncRNA microarray data are shown in Table S3 . Figure 5 ).
F I G U R E 2
The relative expression levels of lncRNAs in gastric cancer cell lines and culture media. A-C, Quantitative real-time polymerase chain reaction (real-time PCR) was used to measure the lncRNAs in gastric cells. b-actin was used as normalization control. D-F, The expression levels of the lncRNAs in culture media were measured using real-time PCR. Data presented as fold change. Data are shown as mean AE SD, n = 3. *P < .05 LIU ET AL.
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| Correlation between the markers
To investigate the similarity in expression levels among the three lncRNAs, Pearson correlation coefficients were calculated for each marker. As presented in Table 1 , the expression level of AC100830.4 showed a mutual relation with CTC-501O10.1 with a coefficient of 0.463 (P < .01) and also mutually related with RP11-210K20.5 with a coefficient of 0.268(P < .01).
| The correlation between expression level of lncRNAs and patient characteristics
We examined the correlations between the expression levels of cir- (Table S4) .
| DISCUSSION
In recent years, numerous studies have demonstrated that ncRNAs (lncRNAs, miRNAs and circular RNAs) are differentially expressed in cancer tissues and bodily fluids, that they often play regulatory roles in biological procedures, and that they have highly specific expression among different tissues. 23, 24 It has been demonstrated that miRNAs and lncRNAs are both stable in the plasma, even in extreme conditions and also resistant to RNase A. [25] [26] [27] These features make it plausible that ncRNAs could be used as diagnostic biomarkers for many types of cancer. 28 For example, PCA3 is a significantly upregulated lncRNA in prostate cancer tissue and metastatic sites, and, based on a real-time PCR assay, PCA3 is dysregulated in the urine of patients with prostate cancer. It has thus been reported to have clinical use as a diagnostic biomarker.
29,30
F I G U R E 3 The relative expression levels of lncRNAs in plasma from patients with gastric cancer and healthy controls. A, The expression level of lncRNA CTC-501O10.1 in plasma was higher in the gastric cancer group (P < .01). B, The expression level of lncRNA AC100830.4 in plasma was higher in the gastric cancer group (P < .01). C, The expression level of lncRNA RP11-210K20.5 in plasma was higher in the gastric cancer group (P < .01)
The AUC for each lncRNA in the training phase. The AUC for lncRNA CTC-501O10.1, lncRNA AC100830.4 and lncRNA RP11-210K20.5 was 0.724, 0.730 and 0.737, respectively. The combined AUC was 0.764 (P < .01)
The AUC for the lncRNA panel in the validation phase. The AUC for the lncRNA panel was 0.700 (P < .01) in an independent cohort consisting of 50 patients with gastric cancer and 50 healthy controls
Because there is still no consensus on an endogenous reference for use with circulating RNAs, we evaluated many common choices and chose b-actin for our endogenous control, consistent with other groups' works. 20, 26 In the current study, we performed a microarray to screen for deregulated lncRNAs in plasma from patients with GC and healthy controls and identified three novel lncRNAs, CTC-501O10.1, AC100830.4 and RP11-210K20.5, which were differentially expressed between these two groups with AUCs of 0.724, 0.730 and 0.737, respectively. The diagnostic potential seems unsatisfactory, yet it is still higher than that of CEA and CA199, as previously reported. 31 The AUC of the single lncRNAs is similar to some previous studies. and miR-497 for cervical cancer detection. 33 Likewise, a lncRNA panel consisting of lnc00152, CFLAR-AS1 and POU3F3 was reportedly used for diagnosing oesophageal squamous cell carcinoma. 34 The combination of three or more biomarkers can significantly elevate the diagnostic potential of blood-based panels. For GC, some panels have been established, but none are widely used in clinical practice. 20, 35 With the aim to increase diagnostic capacity, we combined three lncRNAs using a logistic regression model, resulting in an AUC of 0.764 in the training phase. The panel could provide a moderate diagnostic accuracy, with an AUC of 0.700 in the validation phase. Using the combination of these three lncRNAs, the diagnostic sensitivity was 0.99, which was meaningful in the clinic. To investigate why the panel could not provide a more optimal diagnostic potential, we analysed the correlation between the expression levels of lncRNAs and found that they were mutually related with each other (P < .05). The limited accuracy of the panel could be explained by the correlation in expression between the markers. 36 The specific origins of circulating RNAs are largely unknown. It has been proposed that cancer tissues can secrete lncRNAs into the circulatory system and that they can be protected by nanoscale vesicles called exosomes. Thus, the correlation in expression may be due to the lncRNAs in bodily fluids arising from the same origin. 8, 37 These circulating lncRNAs can be used as biomarkers and could even transfer drug-resistance signals to other sites. 38 CTC-501O10.1 is located on chromosome 17 with a length of 549nt, AC100830.4 is located on Chr21 (q22, 12) with a length of 554nt, and RP11-210K20.5 is located on Chr18 (q12, 1) with a length of 666nt. To the best of our knowledge, none of them have been investigated before. In this study, we found that CTC-501O10.1, AC100830.4, and RP11-210K20.5 could enter into the cell culture medium at a measurable level. And this provided evidence that lncRNAs were released into circulation and the dysregulation of the lncRNAs in circulation could be used as biomarkers for GC.
In our study, we found 3 novel dysregulated lncRNAs in plasma from patients with GC. Using these three lncRNAs, we could distinguish GC patients from healthy controls with better accuracy than some other biomarkers. It is not pessimistic when there was no significant association between the plasma lncRNAs and clinicopathological parameters. Many researchers reported that the lncRNAs in plasma showed no significant correlation with the clinic characteristics, such as some lncRNAs in clear cell renal cell carcinoma, 39 in hepatocellular carcinoma 40 and in gastric cancer. 20, 41 The traditional biomarkers are the most common serum markers used for GC detection. Even in some studies, the traditional biomarkers such as CEA, CA19-9 and CA724 showed no significant correlation with the clinic parameters. 42 Although in the current study, the expression level of the lncRNAs is not correlated with any clinic parameters, but the diagnostic ability of the lncRNAs should not be neglected. They could provide better diagnostic ability than the traditional biomarkers, even better than the combination of CEA, CA19-9 and CA724. 43 Therefore, the circulation lncRNAs are potential diagnostic tools.
Interestingly, even the same lncRNA detected in different cohorts of patients may present different expression pattern. In our study, H19 and HOTAIR showed no significant differences between the plasma of patients with GC and healthy controls, even though it has been previously reported to be elevated in GC plasma. 20, 21, 44 The current study is not the only one argued these discrepancies. H19 was once reported to be up-regulated in plasma from patients with breast cancer; 45 however at almost the meantime, another research reported that H19 was not altered in another cohort of patients with breast cancer. 46 As to HOTAIR, it was also reported not altered in plasma from patients with GC in Otsuji's research, which was consistent with the current study. 41 The inconsistency was not only seen in H19 and HOTAIR, but also in lncRNA MALAT1 20, 47 and some miRNAs. For 44 in which H19 and HOTAIR were up-regulated. Especially, the stage IV patients accounted for 30%-50% in these two studies. While in the current study, there were more early-stage patients enrolled, and the stage IV patients accounted for 17% in the total number of the enrolled patients. Ke et al 48 reported that lncRNAs exist in the plasma as fragments, and this hypothesis may provide another evidence for the inconsistency among the studies. In the hypothesis, different fragments have different expression levels, and different primers in these studies may be complementary with different fragments. They demonstrated that it is necessary to identify the most stable and dysregulated fragments as diagnostic biomarkers. However, this hypothesis is still controversial and needs further investigation. The inconsistency among the studies would be the biggest challenge before the clinic use of the plasma-based-RNA detection.
In summary, our results suggested that the dysregulated lncRNAs in plasma can be used as biomarkers for GC. Combined use of the lncRNAs could provide a higher diagnostic accuracy. However, further
investigations and large-scale case-controlled studies are necessary to fully evaluate this novel option. Much work remains to find novel noninvasive, economic and powerful biomarkers to detect diseases. 
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